Proof-of-concept trial of Goal Management Training
Addiction
Cognitive remediation
Executive function
Goal management training
Impulsivity
Methamphetamine
Journal
Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587
Informations de publication
Date de publication:
01 05 2023
01 05 2023
Historique:
received:
08
10
2022
revised:
30
01
2023
accepted:
13
03
2023
medline:
25
4
2023
pubmed:
3
4
2023
entrez:
2
4
2023
Statut:
ppublish
Résumé
Deficits in executive function are common in methamphetamine use disorder (MUD), likely contributing to difficulties in sustained treatment success. Cognitive remediation interventions are designed to treat such deficits but have not been adapted to the needs of people with MUD. This study presents a proof-of-concept trial to evaluate a new cognitive remediation program for MUD, Goal Management Training This was a cluster-randomised crossover trial comparing GMT GMT GMT
Sections du résumé
BACKGROUND
Deficits in executive function are common in methamphetamine use disorder (MUD), likely contributing to difficulties in sustained treatment success. Cognitive remediation interventions are designed to treat such deficits but have not been adapted to the needs of people with MUD. This study presents a proof-of-concept trial to evaluate a new cognitive remediation program for MUD, Goal Management Training
METHODS
This was a cluster-randomised crossover trial comparing GMT
RESULTS
GMT
CONCLUSIONS
GMT
Identifiants
pubmed: 37004463
pii: S0376-8716(23)00084-4
doi: 10.1016/j.drugalcdep.2023.109846
pii:
doi:
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
109846Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of Interest AVG has received funding from Servier for consultancy work and Elsevier for editorial work. DIL has received travel support and speaker honoraria from Astra Zeneca, Bristol Myers Squibb, Camurus, Indivior, Janssen, Lundbeck, Servier, and Shire.